Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstalliTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
KIT and PDGFRA mutation testing analyzes the molecular changes driving a gastrointestinal stromal tumor (GIST). After surgery, the result helps predict whether the tumor is likely to respond to the tyrosine-kinase inhibitor (TKI) imatinib. It does not, by itself, decide whether treatment is needed: the result must be combined with recurrence-risk features such as tumor size, location, mitotic rate, rupture and surgical margins.
For a completely removed, significant-risk GIST with an imatinib-sensitive KIT or PDGFRA alteration, the standard adjuvant regimen cited by the 2021 ESMO-EURACAN-GENTURIS guideline is imatinib 400 mg once daily for three years. Important exceptions include PDGFRA exon 18 D842V, which predicts primary resistance and should not receive adjuvant imatinib, and KIT exon 9, for which a higher dose may be discussed under specialist supervision.
What KIT and PDGFRA testing measures
GIST cells often depend on abnormal KIT or PDGFRA receptor tyrosine kinases. A mutation in one of these genes can keep the receptor switched on, sending continuous growth signals. TKIs work by blocking that signaling. The molecular test therefore has two jobs: it supports the biological classification of the tumor and predicts whether a particular targeted drug is likely to work.
The test is performed on tumor tissue, usually from a biopsy or the surgical specimen, by a pathology or molecular laboratory. It is not a blood test or a home test. The report may identify a specific gene and exon, describe a mutation as activating, classify the tumor as wild-type when no KIT or PDGFRA mutation is found, or state that the specimen was insufficient for analysis. Your oncology team must interpret the wording in the context of the complete pathology report.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
SEOM-GEIS guidance calls KIT/PDGFRA molecular testing mandatory when adjuvant treatment is indicated. British Sarcoma Group guidance places testing in a sequential algorithm that first establishes whether a patient is an appropriate candidate for TKI treatment. In practice, testing may be ordered earlier so that the result is available when the postoperative decision is made.
Why the result matters after GIST surgery
“Adjuvant” treatment means drug therapy given after the visible tumor has been completely removed, with the aim of reducing the chance that microscopic disease later causes a recurrence. The need for adjuvant treatment is driven primarily by recurrence risk, not by the mutation result alone.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Pathology and surgical factors that determine recurrence risk
| Factor | Why it matters |
|---|---|
| Tumor size | Larger tumors generally carry a greater chance of recurrence than smaller tumors. |
| Anatomic site | Risk estimates differ according to whether the GIST arose in the stomach, small intestine, rectum or another location. |
| Mitotic rate | The number of dividing cells in the tumor is incorporated into risk classifications; a higher rate usually indicates more aggressive biology. |
| Tumor rupture | Rupture can release tumor cells into the abdominal cavity and is an important adverse feature. |
| Surgical margins | The pathology report records whether the resection margins are clear and whether any tumor remains at a margin. |
A mutation can make imatinib biologically appropriate, but a very low-risk tumor may not justify exposing the patient to years of treatment. Conversely, a high-risk tumor with a mutation known to resist imatinib should not receive imatinib simply because its recurrence risk is high.
How the testing and interpretation process works
- Confirm the diagnosis. The pathologist evaluates the resection or biopsy to establish that the tumor is a GIST and records size, site, mitotic rate, rupture status and margins.
- Select suitable tissue. The laboratory uses tumor material from the biopsy or operation. If the sample contains too little tumor or is poorly preserved, the laboratory may report an indeterminate result and the team may need another specimen.
- Analyze KIT and PDGFRA. Molecular testing looks for alterations in these driver genes and identifies the exon and variant when possible.
- Classify likely drug sensitivity. The report is translated into a treatment category: imatinib-sensitive, a mutation with reduced sensitivity, a known resistant alteration, or no KIT/PDGFRA mutation.
- Combine genotype with risk and patient factors. The sarcoma team considers recurrence risk, recovery from surgery, other illnesses, medicines that could interact with a TKI and local regulatory approvals before recommending therapy.
There is no single laboratory turnaround time or specimen protocol that applies to every jurisdiction. Ask the treating center when its laboratory expects the result and whether testing is performed locally or sent to a reference laboratory.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
What common mutation results mean for adjuvant treatment
| Result | Expected imatinib sensitivity | Adjuvant implication after complete resection | Important qualification |
|---|---|---|---|
| Imatinib-sensitive KIT or PDGFRA mutation (often reported as a sensitive KIT exon alteration) | Likely to respond to imatinib | If recurrence risk is significant, ESMO-EURACAN-GENTURIS recommends imatinib 400 mg daily for three years. | The mutation does not override a low-risk classification; risk assessment remains essential. |
| KIT exon 9 | Lower sensitivity to the standard dose | ESMO states that 800 mg daily for three years may be considered in the adjuvant setting. | This is a specialist decision requiring oncology supervision and local approval; do not change the dose yourself. |
| PDGFRA exon 18 D842V | Primary resistance to imatinib | Do not use adjuvant imatinib for this genotype. | NCI also describes these tumors as unlikely to benefit from adjuvant imatinib. Avapritinib is discussed as a genotype-directed option for advanced disease, not as an automatic postoperative substitute. |
| Other PDGFRA alteration | Depends on the exact variant | The treating team must verify whether the alteration is imatinib-sensitive before recommending adjuvant treatment. | An exon number alone is not enough; the specific variant and laboratory interpretation matter. |
| No KIT or PDGFRA mutation (wild-type) | Usually unlikely to benefit from imatinib | Do not infer adjuvant imatinib solely from a high recurrence-risk category. | Further evaluation for SDH-deficient, NF1-associated or other GIST biology may be needed. |
Imatinib-sensitive disease
When the tumor has a mutation expected to respond to imatinib and the recurrence risk is significant, three years of imatinib 400 mg per day is the standard regimen cited by the 2021 ESMO-EURACAN-GENTURIS guideline. The guideline authors describe it as “the standard treatment for patients with a significant risk of relapse.” The prescription begins after the surgical team confirms adequate recovery and the oncology team has reviewed the pathology and medication list.
KIT exon 9
KIT exon 9 is less sensitive to standard-dose imatinib. ESMO allows consideration of 800 mg per day for three years in the adjuvant setting, but this is not a self-directed escalation. Higher dosing can increase treatment burden, and the decision depends on the individual case, local authorization and the oncologist’s assessment of tolerance and interactions.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
PDGFRA exon 18 D842V
D842V is the key resistance exception. The alteration predicts primary resistance, meaning that imatinib is not expected to control the mutation even when the tumor has substantial recurrence risk. ESMO states that PDGFRA exon 18 D842V-mutated GISTs should not receive adjuvant therapy, and the National Cancer Institute likewise says they are unlikely to benefit from adjuvant imatinib. In unresectable or metastatic disease, avapritinib is the genotype-directed option discussed by NCCN and ESMO, but evidence and approvals for advanced disease do not make it an automatic adjuvant replacement after surgery.
Wild-type GIST
“Wild-type” means that the tested tumor has no detectable KIT or PDGFRA mutation. It does not mean that the tumor has no driver biology. SDH-deficient, NF1-associated and other molecular subgroups can underlie a wild-type result. These tumors are generally unlikely to benefit from adjuvant imatinib, so a risk score alone should not trigger treatment. The team may recommend additional pathology or molecular evaluation to clarify the subtype and choose an appropriate surveillance or treatment strategy.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
A practical decision pathway after surgery
- Review the operative and pathology reports. Confirm whether the tumor was completely removed, document margin status and note any rupture.
- Calculate recurrence risk. The team combines size, site, mitotic rate, rupture and margins rather than relying on one feature.
- Check the mutation result. Determine whether the report shows a sensitive KIT/PDGFRA alteration, KIT exon 9, PDGFRA D842V or a wild-type pattern.
- Match treatment to both variables. Significant risk plus an imatinib-sensitive genotype supports adjuvant imatinib. Significant risk plus D842V or most wild-type biology does not automatically support imatinib.
- Choose dose and duration. The usual sensitive-genotype regimen is 400 mg daily for three years; KIT exon 9 may prompt discussion of 800 mg daily for three years under specialist oversight.
- Plan monitoring. The oncology team reviews adverse effects, other medicines, organ function, comorbidities and adherence throughout treatment. Monitoring and dose adjustments are individualized.
Adjuvant treatment is different from treatment for advanced GIST
Mutation-directed choices cannot be transferred automatically between settings. Adjuvant therapy is given after resection when no visible disease remains; advanced therapy is used when GIST is unresectable, recurrent or metastatic. A drug that is appropriate for a resistant genotype in advanced disease may not have evidence or approval as postoperative therapy. This distinction is why avapritinib can be discussed for advanced D842V-mutated GIST while adjuvant imatinib is avoided for the same genotype.
What the test cannot tell you by itself
- It cannot predict the exact date or site of a recurrence.
- It cannot replace the risk classification based on tumor size, location, mitotic rate, rupture and margins.
- It cannot guarantee that a person will tolerate imatinib or remain on treatment for the full planned duration.
- It cannot establish that a wild-type tumor has no actionable biology; SDH, NF1 and other pathways may require separate assessment.
- It cannot justify changing a dose or starting a different TKI without the treating oncology team.
Questions to ask your sarcoma team
- Which gene, exon and exact variant did the laboratory identify?
- Does the report classify the mutation as sensitive, less sensitive or resistant to imatinib?
- What recurrence-risk category results from my tumor size, site, mitotic rate, rupture and margins?
- Is the recommended setting adjuvant treatment after surgery or treatment for recurrent or metastatic disease?
- If KIT exon 9 was found, is an 800 mg dose appropriate and approved where I am being treated?
- If the result is wild-type, should the tumor be evaluated for SDH deficiency, NF1 association or another subtype?
- How will side effects, interactions and adherence be monitored during the planned course?
The central point is that KIT/PDGFRA testing is treatment planning, not merely a diagnostic label. A sensitive mutation can support adjuvant imatinib when recurrence risk is significant; D842V and most wild-type tumors generally should not receive postoperative imatinib; and every result must be interpreted alongside the surgical and pathological record by the treating sarcoma team.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
